BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance ...

Becton, Dickinson and Company (BDX, Financials) announced a major strategic shift with plans to separate its Biosciences and Diagnostic Solutions unit, aiming to create two independent ...

Becton, Dickinson and Company announced it repurchased $750M in BD stock to date in FY25. In addition, the board has authorized the company to repurchase up to 10M shares of BD common stock in ...

Good day, everyone. Welcome to today's Conference Call to discuss BD's First Quarter Fiscal 2025 Earnings and BD's announcement of its Intent to Separate BD's Biosciences and Diagnostic Solutions ...

Revenue: US$5.17b (up 9.8% from 1Q 2024). Net income: US$303.0m (up 7.8% from 1Q 2024). Profit margin: 5.9% (down from 6.0% in 1Q 2024). EPS: US$1.05 (up from US$0.97 in 1Q 2024). Revenue exceeded ...

Becton Dickinson plans to separate its Biosciences and Diagnostic Solutions unit, aiming for completion by fiscal 2026. BD reported Q1 2025 sales of $5.17B, up 9.8% YoY, beating estimates.

Becton Dickinson BDX0.80%increase; green up pointing triangle and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology. Chief Executive ...

Activist investor Starboard Value has taken a position in Becton Dickinson, sending the shares up modestly on Feb. 3. Why it matters: BD shares have been some of the worst performing in the ...

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of ...

Becton Dickinson and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology. Chief Executive Tom Polen said he believes the separation would ...